Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: Oral versus injectable delivery

European Addiction Research

Volumn 13, Issue 4, 2007, Pages 201-206

  Roozen, Hendrik G ^a,c   De Waart, Ranne ^a   Van Den Brink, Wim ^b  

^a Novadic Kentron   (Netherlands)

^b AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alcohol dependence; Naltrexone, depot medication; Systematic review

Indexed keywords

NALTREXONE;

ALCOHOLISM; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INJECTION SITE DISCOMFORT; PAIN; PRIORITY JOURNAL; RISK REDUCTION; SWELLING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ALCOHOLISM; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; NALOXONE; NARCOTIC ANTAGONISTS; RECURRENCE; TREATMENT OUTCOME;

EID: 34548693871     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104882     Document Type: Article

References (33)

1. Davidson D, Palfai T, Bird C, Swift R: Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 1999;23:195-203.
2. Littleton J, Zieglgansberger W: Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003; 12(suppl 1):S3-S11.
3. Bouza C, Magro A, Munoz A, Amate JM: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-828.
4. Srisurapanont M, Jarusuraisin N: Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005;8:267-280.
5. Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS: Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 2003;28:1973-1982.
6. Johnson BA, Ait-Daoud N: Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl) 2000;149:327-344.
7. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP: Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54:737-742.
8. Kranzler HR, Modesto-Lowe V, Nuwayser ES: Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998;22:1074-1079.
9. Alkermes, Press releases 2005. http://www.alkermes.com/news/index.asp?id= 317.
10. Galloway GP, Koch M, Cello R, Smith DE: Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry 2005;5:18.
11. Garbutt JC, Kranzler HR, O'Malley SS, Gast-friend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-1625.
12. Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E: A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004;28:1356-1361.
13. Kranzler HR, Wesson DR, Billot L, Drug Abuse Sciences Naltrexone Depot Study Group: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-1059.
14. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias J, Roberts JS: Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001;21:72-77.
15. Heinälä P, Alho H, Kiianmaa K, Lönnqvist J, Kuoppasalmi K, Sinclair JD: Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind placebo controlled trial. J Clin Psychopharmacol 2001;21:287-292.
16. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al: Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25:1634-1647.
17. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, et al: Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996;53:217-224.
18. Anton RF, Moak DH, Waid LR, Latham P, Malcolm RJ, Dias JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-1764.
19. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E: Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001;96:1565-1573.
20. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992;49:881-887.
21. Feinn R, Kranzler HR: Does effect size in naltrexone trials for alcohol dependence differ for single-site vs multi-center studies? Alcohol Clin Exp Res 2005;29:983-988.
22. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, et al: A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003;27:1142-1149.
23. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al: A multicentre randomized double-blind placebo controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593.
24. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, et al: Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002;22:92-98.
25. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, et al: A double-blind placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002;26:1381-1387.
26. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2003;60:92-99.
27. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group: Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734-1739.
28. Latt NC, Jurd S, Houseman J, Wutzke SE: Naltrexone in alcohol dependence: a randomized clinical trial of effectiveness in a standard clinical setting. Med J Aust 2002;176:530-534.
29. Hersh D, Van Kirk JR, Kranzler HR: Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 1998;139:44-52.
30. Sinclair JD: Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001;36:2-10.
31. Dinarvand R, Moghadam SH, Mohammadyari-Fard L, Atyabi F: Preparation of biodegradable microspheres and matrix devices containing naltrexone. AAPS Pharm Sci Tech 2003;4:E34.
32. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J: Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997;5:324-332.
33. Srisurapanont M, Jarusuraisin N: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2002;2:CD001867.